New hope for kids with lupus: drug trial shows promise
NCT ID NCT01649765
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug belimumab in children aged 5 to 17 with active lupus. Participants received either belimumab or a placebo alongside their usual treatments. The goal was to see if belimumab could safely reduce lupus disease activity over 52 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belimumab (a drug that targets a protein involved in lupus)
What this could lead to
If successful, this could provide a new treatment option to help control lupus in children, reducing disease flares and improving quality of life.
What could go wrong
This is a Phase 2 trial with only 93 participants, so results are preliminary. The drug may not work better than placebo, and side effects like infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Phoenix, Arizona, 85016, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20010, United States
-
GSK Investigational Site
Augusta, Georgia, 30912, United States
-
GSK Investigational Site
St Louis, Missouri, 63104, United States
-
GSK Investigational Site
New York, New York, 10032, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Buenos Aires, C1270AAN, Argentina
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Santa Fe, 5400, Argentina
-
GSK Investigational Site
Calgary, Alberta, T3B 6A8, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 1X8, Canada
-
GSK Investigational Site
Aichi, 474-8710, Japan
-
GSK Investigational Site
Kagoshima, 890-8520, Japan
-
GSK Investigational Site
Miyagi, 989-3126, Japan
-
GSK Investigational Site
Tokyo, 113-8519, Japan
-
GSK Investigational Site
San Luis Potosí City, 78240, Mexico
-
GSK Investigational Site
Lima, Lima 27, Peru
-
GSK Investigational Site
Lima, Lima 5, Peru
-
GSK Investigational Site
Surco, Lima 33, Peru
-
GSK Investigational Site
Lodz, 91-738, Poland
-
GSK Investigational Site
Warsaw, 02-637, Poland
-
GSK Investigational Site
Moscow, 119435, Russia
-
GSK Investigational Site
Saint Petersburg, 194100, Russia
-
GSK Investigational Site
Tolyatti, 445846, Russia
-
GSK Investigational Site
Espluges de Llobregat, 08950, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
-
GSK Investigational Site
Bristol, BS2 8BJ, United Kingdom
-
GSK Investigational Site
Liverpool, L12 2AP, United Kingdom
-
GSK Investigational Site
London, NW1 2PG, United Kingdom
-
GSK Investigational Site
London, WC1N 3JH, United Kingdom